An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report

• Autores principales: Ayako Chida-Nagai (Autor), Takao Tsujioka (Autor), Daisuke Sasaki (Autor), Gaku Izumi (Autor), Hirokuni Yamazawa (Autor), Atsuhito Takeda (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it requires continuous intravenous infusion, whi...